Toronto, ON – The Ontario Institute for Cancer Research (OICR) will receive $420 million over five years from the Ontario government to continue its research into the prevention, early detection, diagnosis and treatment of cancer. The institute will also occupy two floors of Phase II of the MaRS Centre in addition to its current laboratories and offices at its headquarters in the MaRS Centre.
OICR’s current research activities in genomics and bioinformatics will be expanded in the new space in Phase II, allowing the institute to increase its capacity to make new discoveries and move them out of the laboratory into the clinic. The funding will also enable the Ontario Health Study to complete its recruitment plans for the study which will lead to better prevention of cancer and other chronic diseases.
“Over the past five years OICR has networked top scientific talent from the province and recruited 35 international stars of the cancer research world, to meet the cancer challenge,” said Dr Hudson, OICR’s president and scientific director. “We have one of the highest rates of patient enrolment in cancer clinical trials in North America. The trials, conducted in 23 adult and five paediatric cancer centres in Ontario, brings new cancer therapies to Ontario cancer patients sooner. With renewed funding we will continue this important work, ensuring the most promising cancer research in Ontario will be turned into new treatments and provide new hope for cancer patients worldwide.”
OICR says the new expansion will include labs for genomics, informatics and pathology, and will be ready mid-2013. New staff will be hired in 2013 when the building is ready, and additional projects will be announced at some point in the future.